logo
Haunting slave ships found off coast of national park 300 years later: ‘Very convincing'

Haunting slave ships found off coast of national park 300 years later: ‘Very convincing'

New York Post02-05-2025
Archaeologists recently made a startling discovery: They found that two 18th-century shipwrecks off the coast of Central America were actually two Danish slave ships.
The ships, named Fridericus Quartus and Christianus Quintus, are located in shallow waters off Costa Rica's Cahuita National Park.
Advertisement
The 18th-century vessels were shipwrecked in 1710, according to the National Museum of Denmark.
'Fridericus Quartus was set ablaze, while Christianus Quintus had its anchor rope cut, following which the ship was wrecked in the surf,' the museum's press release noted.
'Until now, it has not been clear exactly where the ships were lost.'
Pictures show divers carefully examining the shipwreck, which shows signs of significant decay from the past 315 years.
Advertisement
Though the ships were excavated in 2023, researchers didn't know that they were slave ships until recently.
The vessels were long believed to be pirate ships.
The excavation involved, in part, taking samples from the wood of the ships, as well as yellow bricks that were part of the ship's cargo.
Researchers also conducted dendrochronological analyses — tree-ring dating — to determine where the wood came from.
Advertisement
They found it came from Northern Europe.
The ships, named Fridericus Quartus and Christianus Quintus, were located in the shallow waters off Costa Rica's Cahuita National Park.
Jakob Olling / National Museum of Denmark
'The timbers originate in the western part of the Baltic Sea, an area that encompasses the northeastern German province of Mecklenburg, as well as Schleswig-Holstein, Denmark and Scania — and that the tree was cut down sometime during the years 1690-1695,' the release said.
'The wood is, moreover, charred and sooty, which confirms what historical sources say about one of the ships being set ablaze.'
Advertisement
Divers also found clay pipes, which the museum describes as 'ordinary, Dutch-produced pipes that were also used onboard Danish ships.'
'The size, shape and patterns of the pipes suggest that they were produced in the period right before the ships became wrecked in 1710,' the press release added.
'Clay pipes were rarely used for more than five years.'
The National Museum of Denmark indicates the vessels were shipwrecked in 1710.
Wisconsin Historical Society
Pictures also show the remarkable yellow bricks that survived the shipwreck, which were produced in Flensburg 'for use in Denmark and in the Danish colonies in the 18th and 19th centuries.'
'In other European countries, other kinds of bricks and stones were in fashion when new buildings were erected,' the museum said.
'The clay comes from Denmark — quite specifically, from either Iller Strand or Egernsund,' the statement added.
'Both locations are situated by Flensburg Fjord, which was, in the 18th century, home to a sizeable brick-producing industry.'
Advertisement
After samples from the excavation were analyzed at the National Museum of Denmark and the University of Southern Denmark, researchers concluded the findings corroborate what historical sources say about the history of the ships.
David Gregory, a marine archaeologist at the National Museum of Denmark, said that the results fit 'perfectly' with historical accounts about one of the ships burning.
'The analyses are very convincing and we no longer have any doubts that these are the wrecks of the two Danish slave ships,' Gregory said.
Advertisement
'The bricks are Danish and the same goes for the timbers, which are additionally charred and sooty from a fire. This fits perfectly with the historical accounts stating that one of the ships burnt.'
National Museum of Denmark marine archaeologist Andreas Kallmeyer Bloch said he'd 'come close to giving up' during the long research process – but is stunned by the results.
'This is undoubtedly the craziest archaeological excavation I've yet been part of,' Bach said.
Advertisement
'Not only because it matters greatly to the local population, but also because it's one of the most dramatic shipwrecks in the history of Denmark, and now we know exactly where it happened.'
'This provides two pieces that have been missing from the history of Denmark.'
Fox News Digital reached out to the National Museum of Denmark for additional information.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Immersive 3D Therapy Effective for Voice Hallucinations?
Immersive 3D Therapy Effective for Voice Hallucinations?

Medscape

time5 hours ago

  • Medscape

Immersive 3D Therapy Effective for Voice Hallucinations?

TOPLINE: An immersive virtual reality (VR)-assisted therapy known as Challenge-VRT was associated with a greater reduction in severity and frequency of auditory verbal hallucinations in patients with schizophrenia than enhanced treatment as usual, a new randomized study showed. METHODOLOGY: This randomized parallel-group trial was conducted between 2020 and 2023 across three Danish regions and included adult patients with schizophrenia spectrum disorders (mean age, 33 years; 61% women) who experienced auditory verbal hallucinations for 3 or more months. On average, the patients experienced these voices for 15 years. Participants were randomly assigned to receive either seven weekly sessions plus two booster sessions of Challenge-VRT (n = 140) or matching enhanced treatment as usual (control group; n = 131). Challenge-VRT used a VR avatar of the patient's voice to guide them through phases of empowerment, self-worth development, and recovery while they wore a head-mounted display and engaged in a 3D environment. The primary outcome was clinician-rated severity of auditory verbal hallucinations, as measured by the Psychotic Symptoms Rating Scales-Auditory Hallucinations (PSYRATS-AH) total score at 12 weeks. Secondary outcomes included social functioning, the PSYRATS-AH-Frequency and Distress subscales, and the Voice Power Differential Scale. TAKEAWAY: Compared with the control group, the Challenge-VRT group had a significant reduction in severity of auditory verbal hallucinations (adjusted mean difference, -2.3; P = .03) at 12 weeks. The VR group also showed a significant reduction in hallucination frequency at 12 (P = .02) and 24 (P = .03) weeks. Other secondary outcomes did not differ significantly between the groups. Challenge-VRT was generally well-tolerated, with a 79% completion rate for all seven weekly sessions. Although 37% of participants reported increased hallucination symptoms after the first three sessions, the frequency decreased after the fourth session and continued declining until the end of the study. Serious adverse events potentially related to the VR treatment included five cases of hospital admission due to exacerbation of auditory verbal hallucinations and one episode of self-harm. Additionally, women had higher rates of psychiatric admissions and higher simulation sickness scores than men. IN PRACTICE: 'Challenge-VRT showed short-term efficacy in reducing the severity of auditory verbal hallucinations in patients with schizophrenia, and the findings support further development and evaluation of immersive virtual reality-based therapies in this population,' the investigators wrote. However, Mark Hayward, University of Sussex, Brighton, UK, noted several concerns in an accompanying editorial, including about how to effectively train clinicians to deliver this therapy and why the outcomes weren't sustainable. He also questioned whether a 3D immersive environment is superior to a 2D environment, such as watching something on a computer screen. 'The findings from the Challenge trial suggest that 3D does not add value to avatar therapy. If people with psychosis who are distressed by hearing voices are to build sustainable momentum for their recovery journeys, some of the remaining questions about avatar therapy need to be addressed,' Hayward wrote. SOURCE: The study was led by Lisa Charlotte Smith, PhD, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. It was published online on July 2 in The Lancet Psychiatry. LIMITATIONS: The control group received counseling without a structured treatment manual or formal quality assessment, making direct comparison with Challenge-VRT challenging. Hospitalization data were incomplete, and frequent but undocumented technical problems with the VR system remained unassessed. Key outcome scales were also unreliable or inapplicable for subgroups. Additionally, the real-world sample underrepresented ethnic diversity, and the use of a therapist-controlled, immersive avatar raised ethical concerns about informed consent and off-session effects. DISCLOSURES: The study was funded by The Innovation Fund Denmark, Independent Research Fund Denmark, Innovation Fund North Denmark Region, Psychiatry Research Fund North Denmark Region, and The M L Jørgensen and Gunnar Hansen Fund. Four of the 13 investigators reported having financial ties and research collaborations with Heka VR, who provided the software, and other sources. Full details are provided in the original article. The other investigators and the editorialist reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

What is methylene blue and can it really boost your brain power?
What is methylene blue and can it really boost your brain power?

National Geographic

time4 days ago

  • National Geographic

What is methylene blue and can it really boost your brain power?

The trendy supplement was originally developed as a fabric dye—and later used as a malaria treatment. We asked experts if it really has the cognitive benefits touted on social media. A solution of methylene blue in an erlenmeyer flask. The trending dye was invented by German chemist Heinrich Caro in 1876. Photograph by asikkk, Getty Images If you've spotted someone recently with a blue tongue, that inky stain could actually be the side effect of a new health trend. Biohacking enthusiasts have been using a substance called methylene blue as a daily supplement, sharing videos of their stained tongues on TikTok. Users claim the highly pigmented compound, which was originally developed as a fabric dye before being used for medical purposes, can improve cognitive function, energy levels and mood, and could even prevent Alzheimer's disease. But what do experts have to say? Here's what doctors and researchers say you need to know about potential effects of using methylene blue as a supplement. The history of methylene blue dates back to the late 19th century, when it was synthesized as a textile dye. The trending blue dye was invented in 1876 by German chemist Heinrich Caro. As he was searching for novel dyes for cotton derived from byproducts of the coal industry, one of his experiments accidentally created a vivid blue compound. Methylene blue's chemical structure gives it its signature blue color. 'It absorbs photons of certain wavelengths and the blue photons are the only ones left to be reflected rather than absorbed by the molecule,' explains Dr Roger Rothenberg, assistant professor of clinical medicine at Temple University Hospital's Lewis Katz School of Medicine. In other words, it absorbs all the colors that make up the rainbow spectrum apart from blue, which is reflected back to our eyes, making it appear blue. A decade after Caro's accidental invention, another German scientist, Paul Ehrlich, discovered during an experiment that the organic compound turned parasite cells blue under a microscope. One of the dye's most famous uses is identifying malaria cells and it was later administered in Germany, France and the UK as a treatment for the illness. (To fight malaria, scientists want to poison mosquitoes—with human blood.) 'There was some efficacy for its use in malaria,' Rothenberg says, 'but not as much as the standard treatment for malaria at the time [quinine], so it fell out of favor for that purpose.' What is methylene blue used for? Nowadays, the treatment of methemoglobinemia is methylene blue's only FDA-approved use. Methemoglobinemia is a disorder in which red blood cells can't adequately deliver oxygen to the mitochondria, where it's needed for energy production, leading to symptoms including fatigue, dizziness and shortness of breath. In serious cases, it can be life-threatening. Methylene blue is also still used as a stain in surgical or diagnostic procedures. Physicians have used the compound to help visualize the urinary tract or lymph nodes in colorectal cancer. Methylene blue may be given intravenously for the treatment of methemoglobinemia, a disorder that reduces the blood's ability to carry oxygen. Photograph by James Mutter, Gett Images Initially, methylene blue was initially used for dying textiles. As it turns out, methylene blue is also excellent for dying cell nuclei and cytoplasm, as well as nerve fibers such as the motor neuron above. Micrograph by Ed Reschke, Getty Images Raphael E. Cuomo, scientist and professor at University of California, San Diego School of Medicine, says that as a supplement taken in low doses, methylene blue 'has the potential to enhance mood and energy, and possibly cognitive function, because it inhibits monamine oxidase and also has benefits on mitochondrial activity.' Monamine oxidase (MAO) is an enzyme which breaks down neurotransmitters like serotonin and dopamine. Allowing these feel-good chemicals to flow freely in theory creates a mood boost, while aiding the delivery of oxygen to mitochondria—the 'powerhouses' of cells, can result in more energy. (How to get high on your own hormones—naturally.) However, evidence for these effects in humans is limited, Rothenberg says. 'This is based entirely in theory, from studies on isolated tissue cultures and rats. There are maybe four to six randomized studies in human beings on this general cognition indication. That seems to be the reason people are taking it as a supplement.' For example, a 2021 study of 248 elderly adults found methylene blue administered intravenously significantly reduced postoperative cognitive disorders. Claims that methylene blue can alleviate the symptoms of Alzheimer's disease may be more reasonable, Rothenberg believes. 'The few human studies were done on Alzheimer's patients. There was a statistically significant, though very small, effect of methylene blue in mild to moderate Alzheimer's disease, showing five points [of improvement] on a 70-point scale,' says Bronwyn Holmes. Holmes specializes in regenerative and longevity medicine and says the results should be interpreted with caution. 'A man and a woman who have Alzheimer's, or any neurological disease, they metabolize methylene blue differently, so [the effect may be] very different depending on the patient,' says Holmes. What experts say about oral methylene blue Physicians are seeing the trend of methylene blue used as a supplement skyrocket, thanks in part to viral videos across social media. TikTok specifically is flooded with videos in which users rave about the latest nootropic, meaning a supplement with cognitive benefits. Holmes, who is on the Medical Advisory Board at healthcare provider Eden Health, says she first had patients asking her about the 'neurological benefits' of methylene blue around three years ago. Some experts are skeptical about off-label use of methylene blue as a brain booster. 'Never has a patient come to me with perimenopausal or post-menopausal brain fog, taken methylene blue, and all of a sudden the brain fog has declined,' says Holmes. Rothenberg suggests, 'it's very hard to really prove or disprove these claims when you have individuals taking it rather than a well-controlled, well-designed scientific study.' Due to its vibrant color, methylene blue can also turn human waste products blue or green – a harmless but potentially alarming side effect – and cause teeth staining. 'I had to work with the dentist once because a patient had taken so much meth blue,' Holmes adds. Methylene blue's impact on your health Beyond cosmetic concerns, doctors warn there are a number of health risks associated with consuming methylene blue as a supplement. The most serious is serotonin syndrome, a rare but potentially life-threatening condition which can occur if it is taken in conjunction with selective serotonin reuptake inhibitors (SSRIs), which are widely used to treat depression and anxiety disorders. (What's the right way to wean off antidepressants?) 'If you're on an SSRI, it interacts with methylene blue and compounds the drug's effects,' Holmes explains, causing symptoms of anxiety, fast heart rate, sweating, and tremors. In severe cases, the surge of serotonin can lead to seizures, irregular heartbeat, fever, hallucinations, or loss of consciousness. A 2013 study shows that those with a G6PD deficiency—people missing a key enzyme that protects red blood cells from damage—should avoid methylene blue as it can trigger hemolytic anemia, which is a condition where red blood cells break down rapidly. Less serious side effects can include headache, dizziness, and nausea, while 'at extremely high doses, paradoxically, we see that methylene blue can be causative of methemoglobinemia, which is the very indication it has been approved to treat,' Cuomo says. 'The concern is that people are taking methylene blue as liquid drops, so it is very easy to overdose.' (Why supplements may hurt your health more than help.) If you're concerned about your cognitive health, experts recommend addressing other nutrition and lifestyle factors rather than doing any DIY dosing. 'Unless you really want to turn your toilet bowl blue, there is no compelling reason to take it outside of an indicated medical setting,' says Rothenberg. 'Nootropics that we know absolutely are effective are caffeine, exercise, and appropriate sleep. The latter two specifically are what I would recommend to anyone who wants to boost their cognition.'

Flares Predict AD Severity and Quality of Life
Flares Predict AD Severity and Quality of Life

Medscape

time4 days ago

  • Medscape

Flares Predict AD Severity and Quality of Life

TOPLINE: In a Danish cohort study, the frequency, severity, and duration of flares predicted worse atopic dermatitis (AD) severity and quality of life a year later. METHODOLOGY: Researchers analyzed data from 878 adults with AD (median age in 2022, 49 years; 31.8% men) in the Danish Skin Cohort. Surveys were collected during January-February 2022 and January 2023. Overall, 26.8% of patients had mild AD, 65.5% had moderate AD, and 32.2% had severe AD; 83.2% were actively treated for AD. Researchers collected demographic information, number of flares within the past 12 months, and disease severity measures: Dermatology Life Quality Index (DLQI), Patient-Oriented Scoring of AD, and Patient-Oriented Eczema Measure (POEM). They examined the association between flares reported in 2022 and patient-reported severity measures in 2023 using machine learning models. TAKEAWAY: In 2023, eczema severity as measured by POEM increased with the number of flares reported in 2022. The median score rose from 4.5 among those with no flares to 13 among those with more than 10 flares. The association was significant (quantile regression coefficient, 0.29; 95% CI, 0.20-0.38). In 2023, patients who had more flares in 2022 reported a greater impact on quality of life, as measured by DLQI, although with regards to clinical significance, median DLQI scores indicated a small effect in patient's life (a score of 2-5). The correlation remained significant after adjusting for age, sex, and disease severity in 2022 (regression coefficient, 0.08; 95% CI, 0.04-0.12). Predictive models identified flare severity, number of flares, flare duration, and patient weight as the most important predictors of AD severity 1 year later. Baseline severity scores and prior-year flare counts were strong predictors of flare frequency in the following year. IN PRACTICE: 'The self-reported number of flares in the previous year, in addition to disease severity, duration and severity of the flares, was found to be predictive of future disease severity and frequency of future flares,' the study authors wrote. 'Although a consensus on how many flares are too many remains to be established,' they added, 'the current findings suggest that flares might serve as an early indicator of disease progression or inadequate disease control, highlighting that flares could be relevant in clinical decision making to support optimal treatment strategies.' SOURCE: This study was led by Mia-Louise Nielsen, PhD, Department of Dermatology, Copenhagen University Hospital-Bispebjerg in Copenhagen, Denmark, and was published online on July 16 in JAMA Dermatology. LIMITATIONS: This study relied on self-reported data, with possible potential recall and misclassification biases. DISCLOSURES: Almirall provided funding for this study. Nielsen disclosed receiving personal fees from LEO Pharma. Two other authors reported receiving grants from AbbVie, Novartis, Sanofi, Janssen, UCB, Pfizer, Ebba Celinders Legat, and Else og Mogens Wedell-Wedellsborgs Fond outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store